|
|
Post by slugworth008 on Apr 12, 2020 21:44:44 GMT -5
Yeah I forgot this is a ANTI-MNKD GRIEF Message Board. You want them to be more transparent? HOW?? You really want them to display their strategy to everyone?? Give me a break. You probably bitched about the SECRET Transactions a couple of years ago. You all bitched when Matt was CEO and you all said let's get someone who thinks outside the box. Well we got a young energetic PHARMA Guy and everyone was excited. You guys cant have it both ways. You guys want them issue press releases for every Patent that's issued. You want a CEO that will manipulate the stock price. That's a very short term strategy. Mike has said he is setting this company up for long term growth. That doesn't happen overnight. And you're bitching about the Brazil and India deal. You all were excited about the Brazil filing but remember Mike has said both markets will not have a large impact on expanding MARGINS. IMMIX is a collaboration. It's not a final deal so there are no terms. OK he's being transparent....he issued a PR on the collaboration. They are waiting on government money to finalize a deal. I don't see why you're saying MNKD has poor management. Sales are growing. Brazil is growing. UTHR is in BED with MNKD in a big way. The company is strong. And ALL of this has been done with NO MONEY. Hell the CFO has done a magnificent job and I guess you feel he shouldn't get a bonus. You guys see a glass half empty. I see it as half full. I guess MISERY LOVES COMPANY......I DONE!! Casper, I respect your feelings and opinions of MannKind Executive Management, but I have yet to see you explain how salary increases and/or bonuses for MannKind Executive Management's performance for the year 2019 is both warranted and justified based on their performances, and now, based also in a grand economic meltdown with catastrophic potential, while in the midst of a global pandemic. Like I said, I respect your opinions of Management, however, you have skated around the above so far and I think we all (the 405 MannKind Shareholders who disagree with you) would like for you address it. He can't address it because it simply isn't justified. |
|
|
|
Post by porkini on Apr 12, 2020 22:42:13 GMT -5
Casper, what I/we expect is a lot more transparency from management. You obviously support them. Many of us do not. You are right, there are 3 drug companies that have a lot to lose if Afrezza reaches success anywhere near what Al Mann thought it would. A strong experienced CEO (not a learn on the job guy) would be doing a lot more to defend the share price. That is after all one of the responsibilities of the leader of a public company. The challenge Afrezza has to be a disrupter isn't the first and won't be the last. This management team just doesn't have what it takes to deliver so the share price continues to suffer. The December raise was a gaffe no matter how you try to spin it. The deals Mike has with BIOMM, Cipla, and Immix have no upfront cash. If a CEO can't sell potential partners/companies with cash than this proves he is a horrible negotiator or just picks poor partners. He has said for two years he is working on deals with Mexico and Canada. Where are they? He tossed one away in UAE. I hope sooner rather than later the intsitutional owners who really have the power to make changes at the top sober up and say enough is enough. Otherwise we are at the mercy of a poor management team whose track record will continue to disappoint. And by the way. Don't be smug and tell us we should sell our shares and invest them somewhere else. Many of us longs didn't sell because Mike assured us "he never fails", "we are going to be just fine", "you'll thank me later". And you wonder why we don't think he is entitled to a raise? Let alone continued employment. I have to laugh. Yeah I forgot this is a ANTI-MNKD GRIEF Message Board. You want them to be more transparent? HOW?? You really want them to display their strategy to everyone?? Give me a break. You probably bitched about the SECRET Transactions a couple of years ago. You all bitched when Matt was CEO and you all said let's get someone who thinks outside the box. Well we got a young energetic PHARMA Guy and everyone was excited. You guys cant have it both ways. You guys want them issue press releases for every Patent that's issued. You want a CEO that will manipulate the stock price. That's a very short term strategy. Mike has said he is setting this company up for long term growth. That doesn't happen overnight. And you're bitching about the Brazil and India deal. You all were excited about the Brazil filing but remember Mike has said both markets will not have a large impact on expanding MARGINS. IMMIX is a collaboration. It's not a final deal so there are no terms. OK he's being transparent....he issued a PR on the collaboration. They are waiting on government money to finalize a deal. I don't see why you're saying MNKD has poor management. Sales are growing. Brazil is growing. UTHR is in BED with MNKD in a big way. The company is strong. And ALL of this has been done with NO MONEY. Hell the CFO has done a magnificent job and I guess you feel he shouldn't get a bonus. You guys see a glass half empty. I see it as half full. I guess MISERY LOVES COMPANY......I DONE!! Dead f'n wrong, again! |
|
|
|
Post by barnstormer on Apr 12, 2020 23:11:22 GMT -5
Seriously Casper. You said "I don't see why you're saying MNKD has poor management. Sales are growing. Brazil is growing. UTHR is in BED with MNKD in a big way. The company is strong. And ALL of this has been done with NO MONEY. Hell the CFO has done a magnificent job and I guess you feel he shouldn't get a bonus.
Sales should have been over 1.000 scrips by now. Brazil? You have no idea how much they are contributing. Mike isdn't posting anything. UTHR? There is no gurantee that is going to pan out. The reason "all of this has been done with NO MONEY" is because the CEO can't get a deal done with a partner bringing in big money. Thanks for making my point. GL2U.
|
|
|
|
Post by morfu on Apr 13, 2020 2:07:08 GMT -5
Mannkind managing extreme:
One year take out a ridiculous loan lets say $500mil and easily gain a 1000% performance for the cash at hands
Next year dilute the company shares by 100% to pay of that debt and gain again 1000% performance for "cleaning up the balance sheets"
And my critique has nothing to do with the company, the product or the success of this management with various marketing.
But the BoD 2019 performance evaluation giving 40/93 points to cash at hands after a deal in December 2018, where am undisclosed buyer got 20% of this company at a discounted price without any apparent need for cash (the money is still there 15month later) still needs full disclosure and a good explanation!
(and it needs this beforehand the management can ask for another 35% dilution)
I do not believe there were and are no better ways to get $40mil, this is just wrong and piss poor management and should not be rewarded!
|
|
|
|
Post by mango on Apr 13, 2020 7:21:29 GMT -5
Casper, I respect your feelings and opinions of MannKind Executive Management, but I have yet to see you explain how salary increases and/or bonuses for MannKind Executive Management's performance for the year 2019 is both warranted and justified based on their performances, and now, based also in a grand economic meltdown with catastrophic potential, while in the midst of a global pandemic. Like I said, I respect your opinions of Management, however, you have skated around the above so far and I think we all (the 405 MannKind Shareholders who disagree with you) would like for you address it. Come on Mango...You're smarter than this. 1. UTHR Partnership is strong and progressing nicely - Phase 3 is about to end in August and yes MNKD still has work to do on their end. 2. Brazil started selling in 2019 and is up and running. 3. Mike has cut the burn rate from $25 to $10 per Qtr. over 3 years. 4. India trials have started. 5. They have a distributor in Australia and will be filing soon. 6. Mike and Steve negotiated BIOMM so that all Revenues drop to the bottom line INSTANTLY which was the trade off for upfront money. 7. Kendall has been traveling the world pushing Afrezza at all conferences. 8. Pediatric CoHorts were developed and completed in 2019 and will be filing in the next 2-3 months. 9. Mike has advanced the pipeline with their candidates. 10. Mike met the UTHR Deadlines to get $25 Million in Milestones 11. Mike finally got Deerfield out of their hair. 12. Mike and Steve brought Mid Cap onboard to give them more runway. And for those who think the Dec. 2018 capital raise was Bullshit......Well think about this.....What type of deal would Mike have gotten without that extra money? I'm not sure Mid Cap would have stepped up to the plate with their deal and if they did it would have been a deal similar to Deerfield. Now you might not think all of this progress deserves a BONUS or the scheduled 2% raise and we all know it's up to the Compensation Committee but I'll go as far as to say he'll probably get 75% of his Target. MNKD is a much stronger company. MNKD is right sized right now. Doctors are asking to see their Afrezza Sales Reps MORE OFTEN. Drop the Mic. You did not list a single thing that warrants or justifies increases in salaries and/or bonuses. When you're ready to provide examples of things MannKind Executive Management did in 2019 that warrants increases in salaries and/or bonuses—instead of listing things that are merely part of their given job duties and have nothing to do with going above and beyond—then please post them because we would all like to be aware of those things, too. |
|
|
|
Post by sportsrancho on Apr 13, 2020 7:48:41 GMT -5
|
|
|
|
Post by sportsrancho on Apr 13, 2020 8:06:44 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 13, 2020 8:19:00 GMT -5
Come on Mango...You're smarter than this. 1. UTHR Partnership is strong and progressing nicely - Phase 3 is about to end in August and yes MNKD still has work to do on their end. 2. Brazil started selling in 2019 and is up and running. 3. Mike has cut the burn rate from $25 to $10 per Qtr. over 3 years. 4. India trials have started. 5. They have a distributor in Australia and will be filing soon. 6. Mike and Steve negotiated BIOMM so that all Revenues drop to the bottom line INSTANTLY which was the trade off for upfront money. 7. Kendall has been traveling the world pushing Afrezza at all conferences. 8. Pediatric CoHorts were developed and completed in 2019 and will be filing in the next 2-3 months. 9. Mike has advanced the pipeline with their candidates. 10. Mike met the UTHR Deadlines to get $25 Million in Milestones 11. Mike finally got Deerfield out of their hair. 12. Mike and Steve brought Mid Cap onboard to give them more runway. And for those who think the Dec. 2018 capital raise was Bullshit......Well think about this.....What type of deal would Mike have gotten without that extra money? I'm not sure Mid Cap would have stepped up to the plate with their deal and if they did it would have been a deal similar to Deerfield. Now you might not think all of this progress deserves a BONUS or the scheduled 2% raise and we all know it's up to the Compensation Committee but I'll go as far as to say he'll probably get 75% of his Target. MNKD is a much stronger company. MNKD is right sized right now. Doctors are asking to see their Afrezza Sales Reps MORE OFTEN. Drop the Mic. Doctors are more often asking to see Afrezza reps? Said Mc? YES....Mike said on one of the recent conference calls that Doctors have been asking to see their reps more. That caused Mike to reconfigure the salesforce and shrink territories so they can be closer to the doctors. Th Reps territories were too large and were spending a lot of DRIVE TIME. This is also the time when Mike decided to focus on Type 1 Endos and pullback from the Type 2 Market. Type 2's will take more time and energy because most are not on insulin and getting approval was troublesome. Plus with the Type 2 Study about the DROP this will give MNKD more ammunition and DATA to present to PCP's, Endos and PAYORS. |
|
|
|
Post by mango on Apr 13, 2020 8:26:28 GMT -5
@chuckbass
Since you made our point that there was not a single thing MannKind Executive Management did in 2019 that warrants salary increases and/or bonuses—that the Executive Management team simply performed his/her job duties within its boundaries, and not a single significant event justifies compensation increases—furthermore, just to make matters even worse for your case, you did not list a single event that could possibly warrant or justify salary increases and/or bonuses in light of a grand, nationwide economic meltdown and global pandemic.
Therefore, MannKind Executive Management should forfeit any and all compensation increases being awarded to them for their 2019 performances, and do at least one of the following with that said money:
• Donate the money to a diabetes charity/organization such a JDRF
• Start a MannKind Scholarship Fund and donate the money into it
• Put the money back into the Company to help fund the pipeline or something similar
• Donate the money to their local community in Danbury, CT for those in need
Any one of those 4 suggestions would be a righteous and noble thing to do, and I think even you can agree it would be more beneficial for them to do that versus accepting compensation increases that are not warranted nor justified—and, hypothetically speaking, even if they were warranted/justified it would still be the morally right and noble thing to do given the Company's, the Country's and the World's current situation.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 13, 2020 8:41:06 GMT -5
Seriously Casper. You said "I don't see why you're saying MNKD has poor management. Sales are growing. Brazil is growing. UTHR is in BED with MNKD in a big way. The company is strong. And ALL of this has been done with NO MONEY. Hell the CFO has done a magnificent job and I guess you feel he shouldn't get a bonus. Sales should have been over 1.000 scrips by now. Brazil? You have no idea how much they are contributing. Mike isdn't posting anything. UTHR? There is no gurantee that is going to pan out. The reason "all of this has been done with NO MONEY" is because the CEO can't get a deal done with a partner bringing in big money. Thanks for making my point. GL2U. Why am I going to respond to you??? I DONT KNOW.... But BARN.....TRY HARDER. Who says Sales are supposed to be over 1,000 by now? Mike said the hockey doesn't happen until YEAR 3 which we are in now and we topped around 8XX in the 1st Qtr? Sales are growing YOY - FACT 1. Brazil?? We KNOW Brazil issued a Purchase Order in the 4th Qtr. We KNOW Brazil issued another PURCHASE ORDER in 1st Qtr and revenue will be recorded in the 1st & 2nd Qtr. If BIOMM was not selling Afrezza they would not be asking for more AFREZZA - FACT #2. Mike is not supposed to "POST" anything - FACT #3. We KNOW UTHR has given over $100 MILLION to MNKD so far and BOTH CEO's have talked openly about how great the relationship is - FACT #4. Now comes the FINALE.....MNKD has a BRAND NEW TECHNOLOGY that is UNTESTED and UNPROVEN except for 1 drug which is a HORMONE. So of course no BIG PHARMA is going to stick their neck out with a HUGE DEAL for TS until they see PROOF on real drugs. Especially with the condition of the Pharmaceutical Companies. They want a sure thing before they go out and spend big money. Technosphere is an UNPROVEN PLATFORM at this point in time. When the results are released about TreT and the patients see the benefits......the royalties will start rolling in. Here's an idea.... who says BIG PHARMA didn't want to make a deal with MNKD?? Maybe they have and Mike turned them down because IT WASN'T A GOOD DEAL FOR MNKD?? CHEW ON THAT!!!! |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 13, 2020 8:45:31 GMT -5
Come on Mango...You're smarter than this. 1. UTHR Partnership is strong and progressing nicely - Phase 3 is about to end in August and yes MNKD still has work to do on their end. 2. Brazil started selling in 2019 and is up and running. 3. Mike has cut the burn rate from $25 to $10 per Qtr. over 3 years. 4. India trials have started. 5. They have a distributor in Australia and will be filing soon. 6. Mike and Steve negotiated BIOMM so that all Revenues drop to the bottom line INSTANTLY which was the trade off for upfront money. 7. Kendall has been traveling the world pushing Afrezza at all conferences. 8. Pediatric CoHorts were developed and completed in 2019 and will be filing in the next 2-3 months. 9. Mike has advanced the pipeline with their candidates. 10. Mike met the UTHR Deadlines to get $25 Million in Milestones 11. Mike finally got Deerfield out of their hair. 12. Mike and Steve brought Mid Cap onboard to give them more runway. And for those who think the Dec. 2018 capital raise was Bullshit......Well think about this.....What type of deal would Mike have gotten without that extra money? I'm not sure Mid Cap would have stepped up to the plate with their deal and if they did it would have been a deal similar to Deerfield. Now you might not think all of this progress deserves a BONUS or the scheduled 2% raise and we all know it's up to the Compensation Committee but I'll go as far as to say he'll probably get 75% of his Target. MNKD is a much stronger company. MNKD is right sized right now. Doctors are asking to see their Afrezza Sales Reps MORE OFTEN. Drop the Mic. You did not list a single thing that warrants or justifies increases in salaries and/or bonuses. When you're ready to provide examples of things MannKind Executive Management did in 2019 that warrants increases in salaries and/or bonuses—instead of listing things that are merely part of their given job duties and have nothing to do with going above and beyond—then please post them because we would all like to be aware of those things, too. WTF are you talking about? All that I listed will be on Mike's Evaluation for the year. I promise you that. You're ridiculous. |
|
|
|
Post by rfogel on Apr 13, 2020 8:47:52 GMT -5
Doctors are more often asking to see Afrezza reps? Said Mc? YES....Mike said on one of the recent conference calls that Doctors have been asking to see their reps more. That caused Mike to reconfigure the salesforce and shrink territories so they can be closer to the doctors. Th Reps territories were too large and were spending a lot of DRIVE TIME. This is also the time when Mike decided to focus on Type 1 Endos and pullback from the Type 2 Market. Type 2's will take more time and energy because most are not on insulin and getting approval was troublesome. Plus with the Type 2 Study about the DROP this will give MNKD more ammunition and DATA to present to PCP's, Endos and PAYORS. Sorry but I have a really, really difficult time believing that doctors were "asking to see their reps more." No, I think the effort "to reconfigure the salesforce and shrink territories" was simply to save money. I vaguely recall reading something to the effect that some territories were dominated by managed care companies with policies so restrictive of sales reps that there was simply no point in having reps there. |
|
|
|
Post by mango on Apr 13, 2020 8:59:47 GMT -5
You did not list a single thing that warrants or justifies increases in salaries and/or bonuses. When you're ready to provide examples of things MannKind Executive Management did in 2019 that warrants increases in salaries and/or bonuses—instead of listing things that are merely part of their given job duties and have nothing to do with going above and beyond—then please post them because we would all like to be aware of those things, too. WTF are you talking about? All that I listed will be on Mike's Evaluation for the year. I promise you that. You're ridiculous. Those are things that fall well within the scope of his given job duties. Merely just doing your job does not warrant nor justify an increase in salary and/or bonuses. Again, what are the significant things that Executive Management did that warrants/justifies salary increases and/or bonuses for their 2019 performance? You becoming hostile and defensive with capitalized punctuation does not help your case either. Please address the issue and stop listing things that were expected of Executive Management and that fall within their given job duties. |
|
bkdmd
Researcher
Posts: 79
|
Post by bkdmd on Apr 13, 2020 9:17:45 GMT -5
Seriously Casper. You said "I don't see why you're saying MNKD has poor management. Sales are growing. Brazil is growing. UTHR is in BED with MNKD in a big way. The company is strong. And ALL of this has been done with NO MONEY. Hell the CFO has done a magnificent job and I guess you feel he shouldn't get a bonus. Sales should have been over 1.000 scrips by now. Brazil? You have no idea how much they are contributing. Mike isdn't posting anything. UTHR? There is no gurantee that is going to pan out. The reason "all of this has been done with NO MONEY" is because the CEO can't get a deal done with a partner bringing in big money. Thanks for making my point. GL2U. Why am I going to respond to you??? I DONT KNOW.... But BARN.....TRY HARDER. Who says Sales are supposed to be over 1,000 by now? Mike said the hockey doesn't happen until YEAR 3 which we are in now and we topped around 8XX in the 1st Qtr? Sales are growing YOY - FACT 1. Brazil?? We KNOW Brazil issued a Purchase Order in the 4th Qtr. We KNOW Brazil issued another PURCHASE ORDER in 1st Qtr and revenue will be recorded in the 1st & 2nd Qtr. If BIOMM was not selling Afrezza they would not be asking for more AFREZZA - FACT #2. Mike is not supposed to "POST" anything - FACT #3. We KNOW UTHR has given over $100 MILLION to MNKD so far and BOTH CEO's have talked openly about how great the relationship is - FACT #4. Now comes the FINALE.....MNKD has a BRAND NEW TECHNOLOGY that is UNTESTED and UNPROVEN except for 1 drug which is a HORMONE. So of course no BIG PHARMA is going to stick their neck out with a HUGE DEAL for TS until they see PROOF on real drugs. Especially with the condition of the Pharmaceutical Companies. They want a sure thing before they go out and spend big money. Technosphere is an UNPROVEN PLATFORM at this point in time. When the results are released about TreT and the patients see the benefits......the royalties will start rolling in. Here's an idea.... who says BIG PHARMA didn't want to make a deal with MNKD?? Maybe they have and Mike turned them down because IT WASN'T A GOOD DEAL FOR MNKD?? CHEW ON THAT!!!! or maybe MC turned it down because it wasn't a good deal for him. He has a trackrecord of putting himself before shareholders. |
|
|
|
Post by mango on Apr 13, 2020 9:31:32 GMT -5
This is a really good article written by the Economic Policy Institute concerning CEO pay and Shareholders. I encourage everyone to read it, regardless of your stance here. @chuckbass I suggest you pay special close attention to what I highlighted in red and read the article. Reining in CEO compensation and curbing the rise of inequalityWhat this report finds: Since the 1970s, rapidly accelerating CEO pay has exacerbated inequality in the United States: High CEO pay generates pay increases for other high-level managers, while pay at the middle and bottom of the wage distribution continues to be depressed. Increasing CEO pay is not actually linked to an increase in the value of CEOs’ work; instead, it is more likely to reflect CEOs’ close ties with the corporate board members who set their pay. While corporate boards technically report to shareholders, shareholders are not particularly well positioned to put pressure on directors to restrain CEO pay. Why it matters: CEO pay is not just a symbolic issue. High CEO pay spills over into the rest of the economy and helps pull up pay for privileged managers in the corporate and even nonprofit spheres. Because pay for top managers—CEOs and others—is not driven by their contributions to economic growth, this pay can be reduced and others’ incomes boosted if we can figure out a way to restrain CEOs’ market power. Importantly, the most direct damage done by excess CEO pay is to shareholders. Since shareholders are a relatively privileged group themselves (if not as privileged as CEOs), they could potentially wield power in this situation; policymakers should try to figure out how to enlist shareholders in the fight to restrain excess managerial pay. What can be done about it: Policies should be passed that boost both the incentive for and the ability of shareholders to exercise greater control over excess CEO pay. Tax policy that penalizes corporations for excess CEO-to-worker pay ratios can boost incentives for shareholders to restrain excess pay. To boost the power of shareholders, fundamental changes to corporate governance have to be made. One key example of such a fundamental change would be to provide worker representation on corporate boards. Finally, as a starting point, the Securities and Exchange Commission (SEC) should change the reporting requirements for corporations calculating their CEO-to-worker pay ratios to make them consistent over time and across firms; this will make these ratios far more useful to policymakers and the public. www.epi.org/publication/reining-in-ceo-compensation-and-curbing-the-rise-of-inequality/ |
|
